ES2528347T3 - Derivado peptídico insulinotrópico en el que se ha modificado su aminoácido n-terminal - Google Patents

Derivado peptídico insulinotrópico en el que se ha modificado su aminoácido n-terminal Download PDF

Info

Publication number
ES2528347T3
ES2528347T3 ES12185376.6T ES12185376T ES2528347T3 ES 2528347 T3 ES2528347 T3 ES 2528347T3 ES 12185376 T ES12185376 T ES 12185376T ES 2528347 T3 ES2528347 T3 ES 2528347T3
Authority
ES
Spain
Prior art keywords
modified
insulinotropic peptide
amino acid
terminal amino
peptide derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12185376.6T
Other languages
English (en)
Inventor
Young Hoon Kim
Sung Youb Jung
Se Chang Kwon
Sung Min Bae
Gwan Sun Lee
Dae Hae Song
Chang Ki Lim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Science Co Ltd
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Application granted granted Critical
Publication of ES2528347T3 publication Critical patent/ES2528347T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un péptido insulinotrópico modificado, en el que el resto de histidina N-terminal del péptido insulinotrópico se sustituye por beta-hidroxi imidazopropionil.

Description

imagen1
imagen2
imagen3
imagen4
imagen5

Claims (1)

  1. imagen1
ES12185376.6T 2007-07-16 2008-07-16 Derivado peptídico insulinotrópico en el que se ha modificado su aminoácido n-terminal Active ES2528347T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20070071071 2007-07-16
KR20070071071 2007-07-16
US99115507P 2007-11-29 2007-11-29
US991155P 2007-11-29

Publications (1)

Publication Number Publication Date
ES2528347T3 true ES2528347T3 (es) 2015-02-09

Family

ID=40260219

Family Applications (3)

Application Number Title Priority Date Filing Date
ES12185370.9T Active ES2528346T3 (es) 2007-07-16 2008-07-16 Derivado de péptido insulinotrópico en el que se ha modificado su aminoácido N-terminal
ES12185376.6T Active ES2528347T3 (es) 2007-07-16 2008-07-16 Derivado peptídico insulinotrópico en el que se ha modificado su aminoácido n-terminal
ES11162132.2T Active ES2444622T3 (es) 2007-07-16 2008-07-16 Derivado peptídico insulinotrópico en el que se ha modificado su aminoácido N-terminal

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES12185370.9T Active ES2528346T3 (es) 2007-07-16 2008-07-16 Derivado de péptido insulinotrópico en el que se ha modificado su aminoácido N-terminal

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES11162132.2T Active ES2444622T3 (es) 2007-07-16 2008-07-16 Derivado peptídico insulinotrópico en el que se ha modificado su aminoácido N-terminal

Country Status (22)

Country Link
US (1) US9422349B2 (es)
EP (4) EP2537861B1 (es)
JP (7) JP2009019027A (es)
KR (1) KR101231431B1 (es)
CN (2) CN104672319B (es)
AR (1) AR067555A1 (es)
AU (1) AU2008276762A1 (es)
BR (1) BRPI0814097A8 (es)
CA (3) CA2789112C (es)
DK (1) DK2390265T3 (es)
ES (3) ES2528346T3 (es)
HK (1) HK1207088A1 (es)
IL (1) IL203288A (es)
MY (1) MY167486A (es)
NZ (3) NZ596828A (es)
PH (2) PH12014500923A1 (es)
PT (1) PT2390265E (es)
RU (1) RU2442792C2 (es)
SG (3) SG183033A1 (es)
TW (3) TWI454276B (es)
WO (1) WO2009011544A2 (es)
ZA (1) ZA201000125B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
AU2010225523B2 (en) * 2009-03-20 2012-05-24 Hanmi Science Co., Ltd. Method for preparing a site-specific physiologically active polypeptide conjugate
RU2012126101A (ru) 2009-11-23 2013-12-27 АМИЛИН ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи,США Полипептидный конъюгат
KR101382593B1 (ko) * 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
BR112013007442A2 (pt) 2010-09-28 2019-09-24 Amylin Pharmaceuticals Llc polipeptídeos construídos tendo duração de ação realçada
PT2621519T (pt) 2010-09-28 2017-10-04 Aegerion Pharmaceuticals Inc Polipéptido de fusão de leptina-abd com duração de ação melhorada
EP2714069A4 (en) 2011-05-25 2015-06-24 Amylin Pharmaceuticals Llc LONG-TERM CONJUGATES WITH TWO HORMONES
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
WO2013009545A1 (en) 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action with reduced immunogenicity
WO2013009539A1 (en) 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action and reduced immunogenicity
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
CN103130889A (zh) * 2012-06-15 2013-06-05 中国药科大学 一种Exendin-4类似物及其制备方法和应用
AR092862A1 (es) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
US10441665B2 (en) 2012-07-25 2019-10-15 Hanmi Pharm. Co., Ltd. Liquid formulation of long acting insulinotropic peptide conjugate
KR20140088837A (ko) * 2013-01-03 2014-07-11 한미약품 주식회사 Ｎ-말단 전하가 변형된 인슐린 분비 펩티드 유도체
AR096891A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
AR096890A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn
PE20161153A1 (es) 2014-01-20 2016-10-27 Hanmi Pharm Ind Co Ltd Insulina de accion prolongada y uso de la misma
ES2897935T3 (es) 2014-03-31 2022-03-03 Hanmi Pharm Ind Co Ltd Método para mejorar la solubilidad de proteína y péptido mediante el uso del enlace a un fragmento Fc de inmunoglobulina
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
ES2978112T3 (es) 2015-07-24 2024-09-05 Hanmi Pharmaceutical Co Ltd Método de preparación de un conjugado polipeptídico fisiológicamente activo
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
AU2016343775B2 (en) * 2015-10-28 2021-07-29 Tufts Medical Center Novel polypeptides with improved proteolytic stability, and methods of preparing and using same
BR112019005637A2 (pt) 2016-09-23 2019-07-30 Hanmi Pharm Ind Co Ltd análogos da insulina com afinidade reduzida para o receptor de insulina e seu uso
US20200078470A1 (en) 2016-12-05 2020-03-12 Hanmi Pharm. Co., Ltd. Conjugate with attenuated immune response
KR102645064B1 (ko) 2017-02-03 2024-03-08 한미약품 주식회사 지속성이 증가된 생리활성 물질의 결합체 및 이의 용도
CA3054899A1 (en) 2017-03-23 2018-09-27 Hanmi Pharm. Co., Ltd. Insulin analog complex with reduced affinity for insulin receptor and use thereof
WO2022266467A2 (en) 2021-06-17 2022-12-22 Dana-Farber Cancer Institute, Inc. Recombinant histone polypeptide and uses thereof
KR20230000682A (ko) 2021-06-25 2023-01-03 한미약품 주식회사 심혈관 질환 또는 신장 기능장애 발생의 위험을 감소시키기 위한 에페글레나타이드
KR20230010571A (ko) 2021-07-12 2023-01-19 한미약품 주식회사 Glp-1 유사체를 함유하는 경구 투여 제형 조성물
WO2023194390A1 (en) * 2022-04-08 2023-10-12 Danmarks Tekniske Universitet Histidine methyltransferase for increased peptide and protein stability

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7A (en) * 1836-08-10 Thomas blanchard
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5424686A (en) 1994-04-20 1995-06-13 Philips Electronics North America Corporation Negative-resistance-compensated microwave buffer
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
ES2256888T3 (es) 1996-06-05 2006-07-16 Roche Diagnostics Gmbh Analogos de exendina, proceso para su preparacion y medicamentos que los contienen.
EP1826216A1 (en) * 1996-08-30 2007-08-29 Novo Nordisk A/S Glp-1 derivatives
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
JP2002507188A (ja) 1996-08-30 2002-03-05 イーライ・リリー・アンド・カンパニー グルカゴン様ペプチド―１（ｇｌｐ―１）またはその同族体における外科処置後の異化変調を防止するための使用
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
DK1629849T4 (en) 1997-01-07 2017-12-04 Amylin Pharmaceuticals Llc Pharmaceutical compositions comprising exedins and agonists thereof
US7157555B1 (en) * 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
CA2299425A1 (en) 1997-08-08 1999-02-18 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
EP1938831A1 (en) * 1997-08-08 2008-07-02 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
US7220721B1 (en) * 1997-11-14 2007-05-22 Amylin Pharmaceuticals, Inc. Exendin agonist peptides
US6703359B1 (en) * 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
JP2003522099A (ja) * 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
AU764371B2 (en) 1998-08-28 2003-08-14 Eli Lilly And Company Method for administering insulinotropic peptides
KR20080085082A (ko) * 2000-12-07 2008-09-22 일라이 릴리 앤드 캄파니 Ｇｌｐ-1 융합 단백질
IL141647A0 (en) 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
US6573237B2 (en) * 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
BR0307727A (pt) 2002-02-20 2005-01-25 Lilly Co Eli Fomulação
BR0314996A (pt) * 2002-10-02 2005-08-09 Zealand Pharma As Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
US7790681B2 (en) * 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
AU2003297356A1 (en) * 2002-12-17 2004-07-14 Amylin Pharmaceuticals, Inc. Prevention and treatment of cardiac arrhythmias
JP2006514649A (ja) * 2003-12-17 2006-05-11 アミリン・ファーマシューティカルズ，インコーポレイテッド 腎症の治療および予防のための組成物
TW200611704A (en) * 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
AU2006224537A1 (en) * 2005-03-18 2006-09-21 Novo Nordisk A/S Extended GLP-1 compounds
RU2421237C2 (ru) * 2005-08-19 2011-06-20 Амилин Фармасьютикалз, Инк. Способы лечения диабета и снижения массы тела
WO2007063907A1 (ja) 2005-11-30 2007-06-07 Shionogi & Co., Ltd. ペプチド糖鎖付加体およびそれを有効成分とする医薬
US8501693B2 (en) * 2006-08-04 2013-08-06 Amylin Pharmaceuticals, Llc Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
WO2008145721A2 (en) * 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
US9816387B2 (en) 2014-09-09 2017-11-14 United Technologies Corporation Attachment faces for clamped turbine stator of a gas turbine engine

Also Published As

Publication number Publication date
US20100204451A1 (en) 2010-08-12
JP5481377B2 (ja) 2014-04-23
EP2176289A4 (en) 2010-10-27
EP2390265A2 (en) 2011-11-30
TWI524896B (zh) 2016-03-11
ES2444622T3 (es) 2014-02-26
ES2528346T3 (es) 2015-02-09
EP2537860A1 (en) 2012-12-26
TWI454276B (zh) 2014-10-01
RU2010101232A (ru) 2011-07-27
ZA201000125B (en) 2011-04-28
EP2390265B1 (en) 2013-11-06
WO2009011544A3 (en) 2009-03-19
TWI532496B (zh) 2016-05-11
KR101231431B1 (ko) 2013-02-07
KR20090008151A (ko) 2009-01-21
NZ596828A (en) 2012-03-30
EP2390265A3 (en) 2012-03-21
JP2015172058A (ja) 2015-10-01
JP6023515B2 (ja) 2016-11-09
CA2789112C (en) 2015-01-20
JP2015166368A (ja) 2015-09-24
CA2789123C (en) 2015-01-06
CN101778863A (zh) 2010-07-14
HK1207088A1 (en) 2016-01-22
BRPI0814097A8 (pt) 2016-01-12
EP2176289A2 (en) 2010-04-21
NZ582471A (en) 2012-01-12
SG10201510249PA (en) 2016-01-28
JP2013014598A (ja) 2013-01-24
JP2010533709A (ja) 2010-10-28
SG183033A1 (en) 2012-08-30
IL203288A (en) 2016-02-29
JP6023516B2 (ja) 2016-11-09
MY167486A (en) 2018-08-30
DK2390265T3 (da) 2014-02-10
TW200922615A (en) 2009-06-01
EP2537860B1 (en) 2014-11-26
CA2789123A1 (en) 2009-01-22
PH12014500922A1 (en) 2016-03-07
CN104672319A (zh) 2015-06-03
NZ594853A (en) 2012-03-30
BRPI0814097A2 (pt) 2015-02-03
RU2442792C2 (ru) 2012-02-20
CA2693154C (en) 2014-09-09
CA2693154A1 (en) 2009-01-22
EP2537861A1 (en) 2012-12-26
SG10201510245SA (en) 2016-01-28
PT2390265E (pt) 2014-02-12
CN104672319B (zh) 2020-03-10
CA2789112A1 (en) 2009-01-22
AU2008276762A1 (en) 2009-01-22
US9422349B2 (en) 2016-08-23
AR067555A1 (es) 2009-10-14
TW201311273A (zh) 2013-03-16
TW201311272A (zh) 2013-03-16
PH12014500923A1 (en) 2016-03-07
EP2537861B1 (en) 2014-11-26
WO2009011544A2 (en) 2009-01-22
JP2014094948A (ja) 2014-05-22
JP2009019027A (ja) 2009-01-29
JP2013010779A (ja) 2013-01-17

Similar Documents

Publication Publication Date Title
ES2528347T3 (es) Derivado peptídico insulinotrópico en el que se ha modificado su aminoácido n-terminal
AR112532A2 (es) Compuestos de tetraciclina sustituidos con flúor en c7
ES2575397T3 (es) Uso de péptidos natriuréticos para el tratamiento de síndromes de angioedema
CU20210083A7 (es) Agonistas de glp-1r
AR116395A2 (es) 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida, su monohidrato o sal en una forma de pureza alta
ES2527242T3 (es) Composiciones que comprenden un germinante y un agente antimicrobiano
ECSP12012317A (es) Marcadores predictivos útiles en el tratamiento del síndrome frágil x (fxs)
PA8802301A1 (es) Compuestos que exhiben actividad antagonista del glucagon y agonistas del glp-1
RS52903B (en) BENZOFURANIL DERIVATIVES FOR USE AS GLUCOKINASE INHIBITORS
CL2010001483A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 6-fenil-2h-piridazin-3-ona, inhibidores de tirosina-quinasa (btk); composicion farmaceutica que comprende a dichos compuestos y su uso para el tratamiento de un estado patologico inflamatorio y/o autoinmune.
CL2012002296A1 (es) Polipeptido porque comprende un dominio decimo de fibronectina de tipo iii y que se une a interleucina 23 (il-23); composicion farmacéutica que comprende dicho polipeptido; procedimiento para regular la patogenicidad de los linfocitos th17 que comprende poner en contacto el polipeptido antes mencionado con il-23.
CL2008003690A1 (es) Compuestos derivados de amonobenzamida; composicion farmceutica que comprende los compuestos; y uso para controlar parasitos.
SV2009002865A (es) Uso de oxazolidinonas para el tratamiento y profilaxis de microangiopatias
CL2008002369A1 (es) Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer.
GT200600125A (es) Nueva sal y polimorfos del inhibidor de la dpp-iv
RS52255B (en) NALMEFEN HYDROCHLORIDE DIHYDRATE
ES2546198T3 (es) Tratamiento contra la glomerulonefritis
HN2010001060A (es) 5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas, un proceso para su produccion y su uso como agentes antiinflamatorios.
ES2527454T3 (es) El uso de derivados del péptido Wnt5-a para el tratamiento de melanoma y cáncer gástrico
CL2008001990A1 (es) Compuestos derivados de amino-quinazolinas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer.
CU20200048A7 (es) Triazolobenzazepinas como antagonistas del receptor v1a de la vasopresina
ES2572368T3 (es) Tratamiento de la artrosis
ES2664171T3 (es) Aditivo retardador del fraguado y plastificante para el hormigón
UY32042A (es) Compuestos de 2-aminopirimidina como potentes inhibidores de hsp-90
CL2011000100A1 (es) Uso de un inhibidor de desacetilasa de histona para el tratamiento de la enfermedad de hodgkin.